Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

X
Trial Profile

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HFB 200301 (Primary) ; Tislelizumab (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Germ cell cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Testicular cancer
  • Focus Adverse reactions; First in man
  • Sponsors HiFiBiO
  • Most Recent Events

    • 30 Apr 2024 According to a HiFiBiO Therapeutics media release, data from this study will be presented in the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), set for May 31-June 4, 2024, in Chicago, IL.
    • 14 Dec 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
    • 14 Dec 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top